Search ARM

Archived Publications & Presentations


May 11th 2020

Valuing Transformative Therapies: ASGCT 2020


February 27th 2020

Landscape and Evolution of the Cell & Gene Therapy Marketplace: Public Policy Considerations – IO360

New York City

February 26th 2020

CAR-TCR Europe 2020: ATMP Market Access


February 25th 2020

CAR-TCR Europe 2020: CMC for CAR-T Therapies


February 25th 2020

Blood Centers of America Workshop

New York City

February 7th 2020

Cell And Gene Therapy Innovation Summit

Berlin, Germany

January 22nd 2020

Phacilitate Leaders World 2020

Miami, FL

January 13th 2020

Cell & Gene State of the Industry 2020

San Francisco, CA

December 12th 2019

Getting Ready: EU ATMP Access Event

Brussels, Belgium

October 29th 2019

ICMRA October 2019 Meeting

Rome, Italy

October 28th 2019

ALS-Focused Cell & Gene Therapy Roundtable

Washington, DC

October 23rd 2019

Sindusfarma Fórum sobre Terapias Gênicas y Avançadas 2019

Brasília, Brazil

October 15th 2019

Gene Therapy for Rare Disorders Europe 2019

London, UK

October 10th 2019

Gene Therapies: Sector Overview, New York Academy of Sciences Workshop

New York City

October 7th 2019

Maryland BioInnovation Conference

Rockville, MD

October 3rd 2019

2019 Meeting on the Mesa Day 2

Carlsbad, CA

October 2nd 2019

2019 Meeting on the Mesa Day 1

Carlsbad, CA

September 12th 2019

Cell & Gene Therapy Bioprocessing & Commercialization 2019

Boston, MA

September 12th 2019

Cross-Sector Efforts to Advance Cell & Gene Therapy Manufacturing – CGT Bioprocessing & Commercialization 2019

Boston, MA

August 27th 2019

World Health Organization – Second Expert Advisory Committee to Develop Global Standards for Governance and Oversight of Human Genome Editing

Geneva, Switzerland

July 15th 2019

Business of Regenerative Medicine 2019

Boston, MA

June 13th 2019

Rare Disease Summit 2019: Advancements in Gene Therapy

Boston, MA

April 24th 2019

Meeting on the Med Day 2

Barcelona, Spain

April 23rd 2019

Meeting on the Mediterranean Day 1

Barcelona, Spain

March 28th 2019

3rd Annual Gene Therapy for Rare Disorders

Boston, MA

March 21st 2019

ARM's Cell & Gene Investor Day

New York, New York

February 27th 2019

Blood Centers of America Cell Therapy Workshop

New York, New York

February 7th 2019

DIA Europe 2019 - How to Facilitate Access to ATMPs in Europe

Vienna, Austria

January 23rd 2019

Phacilitate: Leaders World

Miami, Florida

January 7th 2019

2019 State of the Industry Briefing

San Francisco, CA

November 15th 2018

Bipartisan Policy Center Roundtable on Gene Therapy for Neurodegenerative Disease

Washington, DC

October 26th 2018

American Thrombosis and Hemostasis Network Data Summit

Chicago, IL

October 18th 2018

BIA UK Bioscience Forum 2018

London, UK

September 5th 2018

State of the Industry Update - Cell & Gene Therapy: Bioprocessing & Commercialization

Boston, MA

September 4th 2018

Cell & Gene Connect: Evolving Landscape of Cell & Gene Therapies

Boston, MA

May 22nd 2018

Alliance for Regenerative Medicine Policy Lunch

Washington, DC

March 1st 2018

ARM Advanced Therapies Summit


January 1st 2018

ARM 2018 Cell & Gene Therapy State of the Industry

JP Morgan Biotech Showcase, San Francisco

November 1st 2017

ARM European Investor Day




Creating A Roadmap For The Development And Manufacture Of Gene Therapies

May 5th 2020


Bringing Regenerative Medicines to Patients in Need

February 28th 2020

Journal Article

State of the Industry: The Financial, Clinical, and Scientific Landscape for Cell and Gene Therapies

January 31st 2020


The Future of Therapeutic Genome Editing in European Healthcare Systems

September 26th 2019


EU/US Regulatory Analysis Report

July 9th 2019


Getting Ready: Recommendations for Timely Access to ATMPs in Europe

July 8th 2019

In Vivo Article

Manufacturing Cures: Infrastructure Challenges Facing Cell And Gene Therapy Developers

June 10th 2019

Regulatory Focus

Update on Regenerative Medicine Advanced Therapies Designations

May 13th 2019

In Vivo Article

Moving From Chronic Therapies To Cures – Creating A Pathway To Enable New Payment Models

July 23rd 2018

ARM Position Paper

Position on possible solutions to foster development and expand patient access for Advanced Therapy Medicinal Products in Europe

March 14th 2018

Journal of Managed Care Medicine

Ensuring Patient Access to Regenerative and Advanced Therapies in Managed Care: How Do We Get There?

January 1st 2018

ARM Position Paper

Possible solutions to improve the European regulatory procedures for clinical trials with Advanced Therapy Medicinal Products consisting of or containing Genetically Modified Organisms

September 1st 2017


April 10th 2020

FDA Clinical Trial Guidance During COVID-19

This webinar features FDA representatives Tejashri Purohit-Sheth and Ilan Irony from the Office of Tissues and Advanced Therapies, CBER, as they discuss the effect of COVID-19 on cell and gene therapy clinical trials. Discussion topics include assuring the safety of trial participants, maintaining compliance with good clinical practice (GCP), and minimizing risks to trial integrity during the COVID-19 pandemic.

April 7th 2020

Understanding the Coronavirus Emergency Loan Program for Small Businesses

This webinar features speakers Mary Beth Bosco, Nicole Elliott, and Joel Roberson, Partners at Holland & Knight LLP, to discuss the emergency loan program for small businesses established by the Coronavirus Aid, Relief, and Economic Security (CARES) Act. This fiscal stimulus program went live April 3, 2020 and loans will only be available until funds are exhausted, so the government is advising borrowers to apply as soon as possible.

September 19th 2019

Manufacturing Challenges Facing Cell & Gene Therapy Developers

As more regenerative medicine products approach clinical testing and commercialization, seize this opportunity to hear detailed insights and industry best practices from preeminent sector experts. Gain a deeper understanding of the many manufacturing and industrialization hurdles unique to bringing durable and even curative therapies to patients in need.

March 6th 2019

Introducing ARM: Regenerative Medicine in Europe

This webinar is intended to provide members of the press in Europe with an overview of the ATMP landscape in Europe, including major financings, the clinical pipeline, and the potential for these therapies to significantly improve the standard of care for many patients suffering from devastating diseases and disorders. The webinar also provides a brief introduction to ARM and ARM’s role in improving the landscape for ATMPs in Europe and globally.

June 13th 2018

RMAT Designation – Impact on Regenerative Medicine Sector

Gain a deeper understanding of the implications of the Regenerative Medicine Advanced Therapies (RMAT) designation and the significance of its support and advancement by the FDA in this webinar recording. Held in partnership with the Alliance for Regenerative Medicine (ARM), ARM, Informa Pharma Intelligence, and representative from Abeona, Athersys, and Enzyvant discuss the RMAT designation and its implications on the sector.

May 9th 2018

NTAP and the Next Generation of Cures

Michael Werner, Co-Founder and Senior Policy Counsel for ARM, and Robert Falb, Director of U.S. Policy and Advocacy, participated in BIO’s webinar on NTAP and advanced therapies on May 9. ARM believes that it is critical that the NTAP program be modernized to facilitate patient access to new and life-saving treatments.

October 24th 2017

CAR-T Approval: What’s Next?

CAR-T cell therapy is now approved in the U.S. The first product, Novartis’ Kymriah, is approved to treat pediatric and young adult patients with B-cell acute lymphoblastic lymphoma, and products for other oncological indications are hot on its heels. Join Informa Pharma Intelligence and ARM for an interactive webinar to explore what this historic approval means for the patient community, as well as how this sector will approach the scientific, clinical, policy and business issues surrounding CAR-T approvals.

Submitted Comments, Letters, Statements